Cited by 1,521Cancer-related Molecular PathwaysHeat shock proteins researchPI3K/AKT/mTOR signaling in cancer

The DOI matches its Crossref record; 65 of the 72 references it cites were found in a registry or an index.

The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2’s inhibition of p53

Open access

Pomerantz, Jason, Schreiber-Agus, Nicole, Liégeois, Nanette J, Silverman, Adam, Alland, Leila, Chin, Lynda, Potes, Jason, Chen, Ken, Orlow, Irene, Lee, Han-Woong, Cordon-Cardo, Carlos, DePinho, Ronald A·1998·Cell

DOI 10.1016/s0092-8674(00)81400-2

Open this paper in CoChat — free account Open PDF

Abstract

The INK4a gene encodes two distinct growth inhibitors--the cyclin-dependent kinase inhibitor p16Ink4a, which is a component of the Rb pathway, and the tumor suppressor p19Arf, which has been functionally linked to p53. Here we show that p19Arf potently suppresses oncogenic transformation in primary cells and that this function is abrogated when p53 is neutralized by viral oncoproteins and dominant-negative mutants but not by the p53 antagonist MDM2. This finding, coupled with the observations that p19Arf and MDM2 physically interact and that p19Rrf blocks MDM2-induced p53 degradation and transactivational silencing, suggests that p19Arf functions mechanistically to prevent MDM2's neutralization of p53. Together, our findings ascribe INK4a's potent tumor suppressor activity to the cooperative actions of its two protein products and their relation to the two central growth control pathways, Rb and p53.

Integrity signals

Registry

Crossref · 10.1016/s0092-8674(00)81400-2

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Recombinant Genomes Which Express Chloramphenicol Acetyltransferase in Mammalian Cells
Gorman, C., Moffat, L. F., & Howard, B. H. (1982) · Molecular and Cellular Biology · doi:10.1128/mcb.2.9.1044 · Cited by 7,674
Cancer Cell Cycles
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
The retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
The p53 tumour suppressor gene
Levine, A. J., Momand, J. A., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,785
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312

Show all 72 references

Research works printed but not linked: 6

Brenner, 1996, Preferential loss of expression of p16INK4a rather than p19ARF in breast cancer, Clin. Cancer Res., 2, 1993
Elledge, 1996, A question of balance, Trends Biochem. Sci., 6, 388
Kinoshita, 1996, Altered p16INK4 and retinoblastoma protein status in non-small cell lung cancer, Cancer Res., 56, 5557
Quelle, 1995, Cloning and characterization of murine p16INK4a and p15INK4b genes, Oncogene, 11, 635
Schreiber-Agus, 1994, Evolutionary relationships and functional conservation among vertebrate Max-associated proteins, Oncogene, 9, 3167
Schreiber-Agus, 1997, An amino-terminal domain of Mxi1 mediates anti-Myc oncogenic activity and interacts with a homolog of the yeast transcriptional repressor SIN3, Cell, 80, 777, 10.1016/0092-8674(95)90356-9 · DOI

Sorted by citations

Items 201–300 of 1,001

The Max Network Gone Mad
Baudino, T. A., & Cleveland, J. L. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.3.691-702.2001 · Cited by 183
Methylation Silencing and Mutations of the p14ARF and p16INK4a Genes in Colon Cancer
Hirt‐Burri, N., Shaw, P. H., Bouzourène, H., Sordat, I., Sordat, B., Gillet, M., Schorderet, D. F., Bosman, F. T., & Chaubert, P. (2001) · Laboratory Investigation · doi:10.1038/labinvest.3780230 · Cited by 181
Regulation of p53 stability and activity in response to genotoxic stress
Colman, M. S., Afshari, C. A., & Barrett, J. C. (2000) · Mutation Research/Reviews in Mutation Research · doi:10.1016/s1383-5742(00)00035-1 · Cited by 182
Mechanisms of inactivation of p14ARF, p15INK4b, and p16INK4a genes in human esophageal squamous cell carcinoma.
Xing, E. P., Nie, Y., Song, Y., Yang, G., Cai, Y., Wang, L., & Yang, C. S. (1999) · PubMed · Cited by 180
Regulating the p53 system through ubiquitination
Yang, Y., Li, C.-C. H., & Weissman, A. M. (2004) · Oncogene · doi:10.1038/sj.onc.1207411 · Cited by 184
Main roads to melanoma
Palmieri, G., Capone, M., Ascierto, M. L., Gentilcore, G., Stroncek, D. F., Casula, M., Sini, M. C., Palla, M., Mozzillo, N., & Ascierto, P. A. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-86 · Cited by 190
Regulation of the MDM2-P53 pathway and tumor growth by PICT1 via nucleolar RPL11
Sasaki, M., Kawahara, K., Nishio, M., Mimori, K., Kogo, R., Hamada, K., Itoh, B., Wang, J., Komatsu, Y., Yang, Y. R., et al. (2011) · Nature Medicine · doi:10.1038/nm.2392 · Cited by 179
High frequency of p16INK4A gene alterations in hepatocellular carcinoma
Liew, C.-T., Li, H., Lo, K. W., Leow, C. K., Chan, J. Y., Hin, L., Lau, W. Y., Lai, P. B. S., Lim, B. K., Huang, J., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1202359 · Cited by 179
Survival of Patients with Glioblastoma Multiforme is not Influenced by Altered Expression of P16, P53, EGFR, MDM2 or Bcl‐2 Genes
Newcomb, E. W., Cohen, H. W., Lee, S. R., Bhalla, S. K., Bloom, J., Hayes, R. L., & Miller, D. C. (1998) · Brain Pathology · doi:10.1111/j.1750-3639.1998.tb00191.x · Cited by 178
Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 Genes and Their Prognostic Implications in Osteosarcoma and Ewing Sarcoma
Tsuchiya, T., Sekine, K., Hinohara, S.-I., Namiki, T., Nobori, T., & Kaneko, Y. (2000) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(99)00255-1 · Cited by 177
p16Ink4a in Melanocyte Senescence and Differentiation
Sviderskaya, E. V. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.6.446 · Cited by 181
p53 regulation by post-translational modification and nuclear retention in response to diverse stresses
Jimenez, G. S., Khan, S. H., Stommel, J. M., & Wahl, G. M. (1999) · Oncogene · doi:10.1038/sj.onc.1203013 · Cited by 177
Control of p53 ubiquitination and nuclear export by MDM2 and ARF.
Zhang, Y., & Xiong, Y. (2001) · PubMed · Cited by 176
Autoinhibitory Regulation of p73 by ΔNp73 To Modulate Cell Survival and Death through a p73-Specific Target Element within the ΔNp73 Promoter
Nakagawa, T., Takahashi, M., Ozaki, T., Watanabe, K., Todo, S., Mizuguchi, H., Hayakawa, T., & Nakagawara, A. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.8.2575-2585.2002 · Cited by 177
Cutaneous Photobiology. The Melanocyte vs. the Sun: Who Will Win the Final Round?
Kadekaro, A. L., Kavanagh, R. J., Wakamatsu, K., Ito, S., Pipitone, M. A., & ABDEL‐MALEK, Z. A. (2003) · Pigment Cell Research · doi:10.1034/j.1600-0749.2003.00088.x · Cited by 179
Impaired Nonhomologous End-Joining Provokes Soft Tissue Sarcomas Harboring Chromosomal Translocations, Amplifications, and Deletions
Sharpless, N. E., Ferguson, D. O., O’Hagan, R. C., Castrillón, D. H., Lee, C., Farazi, P. A., Alson, S., Fleming, J., Morton, C. C., Frank, K. M., et al. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00425-7 · Cited by 173
Self-citation
The role of p53 in neuronal cell death
Morrison, R. S., & Kinoshita, Y. (2000) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400741 · Cited by 175
A redox mechanism underlying nucleolar stress sensing by nucleophosmin
Yang, K., Wang, M., Zhao, Y., Sun, X., Yang, Y. A., Li, X., Zhou, A., Chu, H., Zhou, H., Xu, J., et al. (2016) · Nature Communications · doi:10.1038/ncomms13599 · Cited by 178
A melanoma-associated germline mutation in exon 1β inactivates p14ARF
Rizos, H., Puig, S., Bádenas, C., Malvehy, J., Darmanian, A., Jiménez, L., Milà, M., & Kefford, R. F. (2001) · Oncogene · doi:10.1038/sj.onc.1204728 · Cited by 171
Senescence Regulation by the p53 Protein Family
Qian, Y., & Chen, X. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-239-1_3 · Cited by 181
Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo
Xirodimas, D., Saville, M. K., Edling, C., Lane, D. P., & Laín, S. (2001) · Oncogene · doi:10.1038/sj.onc.1204656 · Cited by 169
Repression of the Arf tumor suppressor by E2F3 is required for normal cell cycle kineticsPreprint
Aslanian, A., Iaquinta, P. J., Verona, R. I., & Lees, J. A. (2004) · Genes & Development · doi:10.1101/gad.1196704 · Cited by 176
Frequent Methylation Silencing of p15INK4b(MTS2) and p16INK4a (MTS1) in B-Cell and T-Cell Lymphomas
Baur, A. S., Shaw, P., Hirt‐Burri, N., Delacrétaz, F., Bosman, F. T., & Chaubert, P. (1999) · Blood · doi:10.1182/blood.v94.5.1773 · Cited by 168
Germ Line Transmission of the Cdk4R24C Mutation Facilitates Tumorigenesis and Escape from Cellular Senescence
Rane, S. G., Cosenza, S. C., Mettus, R. V., & Reddy, E. P. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.2.644-656.2002 · Cited by 167
Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities
Micevic, G., Theodosakis, N., & Bosenberg, M. (2017) · Clinical Epigenetics · doi:10.1186/s13148-017-0332-8 · Cited by 171
Preferential Inactivation of the p53 Tumor Suppressor Pathway and Lack of EGFR Amplification Distinguish de novo High Grade Pediatric Astrocytomas from de novo Adult Astrocytomas
Sung, T., Miller, D. C., Hayes, R. L., Alonso, M., Yee, H. T., & Newcomb, E. W. (2000) · Brain Pathology · doi:10.1111/j.1750-3639.2000.tb00258.x · Cited by 167
p19ARF targets certain E2F species for degradation
Martelli, F., Hamilton, T., Silver, D. P., Sharpless, N. E., Bardeesy, N. M., Rokas, M., DePinho, R. A., Livingston, D. M., & Grossman, S. R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081061398 · Cited by 167
Self-citation
Dual Inactivation of RB and p53 Pathways in RAS-Induced Melanomas
Bardeesy, N., Bastian, B. C., Hezel, A., Pinkel, D., DePinho, R. A., & Chin, L. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.6.2144-2153.2001 · Cited by 166
Self-citation
Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice
Goel, V., Ibrahim, N., Jiang, G., Singhal, M., Fee, S., Flotte, T. J., Westmoreland, S. V., Haluska, F. S., Hinds, P. W., & Haluska, F. G. (2009) · Oncogene · doi:10.1038/onc.2009.95 · Cited by 176
Deletions of the INK4A Gene Occur in Malignant Peripheral Nerve Sheath Tumors but not in Neurofibromas
Kourea, H. P., Orlow, I., Scheithauer, B. W., Cordon-Cardo, C., & Woodruff, J. M. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65504-6 · Cited by 165
Self-citation
HCV-related hepatocellular carcinoma: From chronic inflammation to cancer
Castello, G., Scala, S., Palmieri, G., Curley, S. A., & Izzo, F. (2009) · Clinical Immunology · doi:10.1016/j.clim.2009.10.007 · Cited by 163
Redox signalling and transition metals in the control of the p53 pathway
Méplan, C., Richard, M., & Hainaut, P. L. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00297-x · Cited by 164
Life and death decisions by E2F-1
Bell, L. A., & Ryan, K. M. (2003) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401324 · Cited by 169
Molecular and Genetic Aspects of Lung Cancer
Rom, W. N., Hay, J. G., Lee, T. C., Jiang, Y., & Tchou-Wong, K.-M. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.4.9908012 · Cited by 163
Inactivation of the p53-homologue p73 by the mdm2-oncoprotein
Dobbelstein, M., Wienzek, S., König, C., & Roth, J. (1999) · Oncogene · doi:10.1038/sj.onc.1202512 · Cited by 161
Human ARF binds E2F1 and inhibits its transcriptional activity
Eymin, B., Karayan, L., Seité, P., Brambilla, C., Brambilla, E. M., Larsen, C., & Gazzéri, S. (2001) · Oncogene · doi:10.1038/sj.onc.1204220 · Cited by 161
Tbx2 Directly Represses the Expression of the p21WAF1 Cyclin-Dependent Kinase Inhibitor
Prince, S., Carreira, S., Vance, K. W., Abrahams, A., & Goding, C. R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3286 · Cited by 165
Melanoma genetics: An update with focus on the CDKN2A(p16)/ARF tumor suppressors
Piepkorn, M. W. (2000) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2000.104687 · Cited by 160
ARF Impedes NPM/B23 Shuttling in an Mdm2-Sensitive Tumor Suppressor Pathway
Brady, S. N., Yu, Y., Maggi, L. B., & Weber, J. D. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.21.9327-9338.2004 · Cited by 163
A CpG island hypermethylation profile of primary colorectal carcinomas and colon cancer cell lines.
Lind, G. E., Thorstensen, L., Løvig, T., Meling, G. I., Hamelin, R., Rognum, T. O., Esteller, M., & Lothe, R. A. (2004) · Molecular Cancer · doi:10.1186/1476-4598-3-28 · Cited by 157
Prognostic Significance of p53 Mutation and p53 Overexpression in Advanced Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study
Havrilesky, L. J., Darcy, K. M., Hamdan, H. B., Priore, R. L., Leon, J., Bell, J., & Berchuck, A. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.052 · Cited by 156
Perturbation of Ribosome Biogenesis Drives Cells into Senescence through 5S RNP-Mediated p53 Activation
Nishimura, K., Kumazawa, T., Kuroda, T., Katagiri, N., Tsuchiya, M., Goto, N., Furumai, R., Murayama, A., Yanagisawa, J., & Kimura, K. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.01.055 · Cited by 167
Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis
Sharp, R., Recio, J. A., Jhappan, C., Otsuka, T., Liu, S., Yu, Y., Liu, W., Anver, M. R., Navid, F., Helman, L. J., et al. (2002) · Nature Medicine · doi:10.1038/nm787 · Cited by 155
Self-citation
TBX-3, the Gene Mutated in Ulnar-Mammary Syndrome, Is a Negative Regulator of p19 and Inhibits Senescence
Brummelkamp, T. R., Kortlever, R. M., Lingbeek, M., Trettel, F., MacDonald, M. E., van Lohuizen, M., & Bernards, R. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110492200 · Cited by 154
The oncogenic potential of Kaposi's sarcoma-associated herpesvirus cyclin is exposed by p53 loss in vitro and in vivo
Verschuren, E. W., Klefström, J. T., Evan, G. I., & Jones, N. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00123-x · Cited by 153
p53 protein aggregation promotes platinum resistance in ovarian cancer
Yang‐Hartwich, Y., Soteras, M. G., Lin, Z. P., Holmberg, J. C., Sumi, N. J., Craveiro, V., Liang, M., Romanoff, E. L., Goodner-Bingham, J., Garofalo, F., et al. (2014) · Oncogene · doi:10.1038/onc.2014.296 · Cited by 152
Tumor suppressor p53: regulation and function
Somasundaram, K. (2000) · Frontiers in bioscience · doi:10.2741/somasund · Cited by 155
Transcription factor E2F‐1 acts as a growth‐promoting factor and is associated with adverse prognosis in non‐small cell lung carcinomas
Gorgoulis, V. G., Zacharatos, P., Mariatos, G., Kotsinas, A., Bouda, M., Kletsas, D., Asimacopoulos, P. J., Agnantis, N. J., Kittas, C. N., & Papavassiliou, A. G. (2002) · The Journal of Pathology · doi:10.1002/path.1121 · Cited by 152
DNA damage induced p53 stabilization: no indication for an involvement of p53 phosphorylation
Blattner, C., Tobiasch, E., Litfen, M., Rahmsdorf, H. J., & Herrlich, P. (1999) · Oncogene · doi:10.1038/sj.onc.1202480 · Cited by 151
Proteasome activator PA28γ regulates p53 by enhancing its MDM2‐mediated degradation
Zhang, Z., & Zhang, R. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.25 · Cited by 151
Diseases of aging
Wick, G., Jansen‐Dürr, P., Berger, P., Blasko, I., & Grubeck‐Loebenstein, B. (2000) · Vaccine · doi:10.1016/s0264-410x(99)00489-2 · Cited by 152
p53, Stem Cells, and Reprogramming: Tumor Suppression beyond Guarding the Genome
Spike, B. T., & Wahl, G. M. (2011) · Genes & Cancer · doi:10.1177/1947601911410224 · Cited by 160
Genetic Epidemiology of Cutaneous Melanoma
Goldstein, A. M., & Tucker, M. A. (2001) · Archives of Dermatology · doi:10.1001/archderm.137.11.1493 · Cited by 150
Cancer-Associated Mutations in the MDM2 Zinc Finger Domain Disrupt Ribosomal Protein Interaction and Attenuate MDM2-Induced p53 Degradation
Lindström, M. S., Jin, A., Deisenroth, C., Wolf, G. W., & Zhang, Y. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.01307-06 · Cited by 149
Novel anticancer drug discovery
Buolamwini, J. K. (1999) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(99)80073-8 · Cited by 149
Strategies for manipulating the p53 pathway in the treatment of human cancer
Hupp, T. R., Lane, D. P., & Ball, K. L. (2000) · Biochemical Journal · doi:10.1042/bj3520001 · Cited by 148
Methylthioadenosine phosphorylase, a gene frequently codeleted with p16(cdkN2a/ARF), acts as a tumor suppressor in a breast cancer cell line.
Christopher, S. A., Diegelman, P., Porter, C. W., & Kruger, W. D. (2002) · PubMed · Cited by 147
Untitled work
(2003) · PubMed · Cited by 147
p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma
Fulci, G., Labuhn, M., Maier, D., Lachat, Y., Hausmann, O., Hegi, M. E., Janzer, R. C., Merlo, A., & Van Meir, E. G. (2000) · Oncogene · doi:10.1038/sj.onc.1203700 · Cited by 146
Potential roles for the PIM1 kinase in human cancer – A molecular and therapeutic appraisal
Shah, N., Pang, B., Yeoh, K. G., Thorn, S., Chen, C. S., Lilly, M. B., & Salto‐Tellez, M. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.06.044 · Cited by 149
Direct repression of the Mcl-1 promoter by E2F1
Croxton, R., Ma, Y., Song, L., Haura, E. B., & Cress, W. D. (2002) · Oncogene · doi:10.1038/sj.onc.1205157 · Cited by 156
Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants
Puntervoll, H. E., Yang, X. R., Høberg‐Vetti, H., Bachmann, I. M., Avril, M.-F., Benfodda, M., Catricalà, C., Dalle, S., Duval‐Modeste, A. B., Ghiorzo, P., et al. (2013) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2012-101455 · Cited by 145
Gene expression patterns associated with the metastatic phenotype in rodent and human tumors.
Nestl, A., von Stein, O. D., Zatloukal, K., Thies, W. G., Herrlich, P. A., Hofmann‐Apitius, M., & Sleeman, J. P. (2001) · PubMed · Cited by 145
Induction of ARF tumor suppressor gene expression and cell cycle arrest by transcription factor DMP1
Inoue, K., Roussel, M. F., & Sherr, C. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3993 · Cited by 144
Hypophosphorylation of Mdm2 Augments p53 Stability
Blattner, C., Hay, T., Meek, D. W., & Lane, D. P. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.17.6170-6182.2002 · Cited by 144
E2F-1 induced apoptosis
Phillips, A. C., & Vousden, K. H. (2001) · APOPTOSIS · doi:10.1023/a:1011332625740 · Cited by 144
Identification of p53 regulators by genome-wide functional analysis
Huang, Q., Raya, Á., DeJesus, P., Chao, S., Quon, K. C., Caldwell, J. S., Chanda, S. K., Izpisúa‐Belmonte, J. C., & Schultz, P. G. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308562100 · Cited by 144
Molecular mechanisms of photocarcinogenesis
Matsumura, Y. (2002) · Frontiers in bioscience · doi:10.2741/matsumur · Cited by 143
Untitled work
(2002) · PubMed · Cited by 143
Self-citation
Conditional Mutation of Rb Causes Cell Cycle Defects without Apoptosis in the Central Nervous System
MacPherson, D. P., Sage, J., Crowley, D. G., Trumpp, A., Bronson, R. T., & Jacks, T. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.3.1044-1053.2003 · Cited by 144
Hypoxia induces p53 accumulation through MDM2 down-regulation and inhibition of E6-mediated degradation.
Alarcon, R. M., Koumenis, C., Geyer, R. K., Maki, C. G., & Giaccia, A. J. (1999) · PubMed · Cited by 143
Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescencePreprint
Zou, X., Ray, D., Aziyu, A., Christov, K. T., Boiko, A. D., Gudkov, A. V., & Kiyokawa, H. (2002) · Genes & Development · doi:10.1101/gad.1033002 · Cited by 146
Ink4a/Arf links senescence and aging
Sharpless, N. E. (2004) · Experimental Gerontology · doi:10.1016/j.exger.2004.06.025 · Cited by 142
A Large Scale shRNA Barcode Screen Identifies the Circadian Clock Component ARNTL as Putative Regulator of the p53 Tumor Suppressor Pathway
Mullenders, J., Fabius, A. W. M., Madiredjo, M., Bernards, R., & Beijersbergen, R. L. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004798 · Cited by 146
Massively regulated genes: the example of TP53
Hollstein, M. C., & Hainaut, P. L. (2009) · The Journal of Pathology · doi:10.1002/path.2637 · Cited by 149
The Emerging p53 Gene Family
Kaelin, W. G. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.7.594 · Cited by 143
TP53 in hematological cancer: Low incidence of mutations with significant clinical relevance
PELLER, S., & Rotter, V. (2003) · Human Mutation · doi:10.1002/humu.10190 · Cited by 141
What we could do now: molecular pathology of bladder cancer
Knowles, M. A. (2001) · Molecular Pathology · doi:10.1136/mp.54.4.215 · Cited by 141
Ubiquitin-proteasome-mediated local protein degradation and synaptic plasticity
Hegde, A. N. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.05.005 · Cited by 143
Cooperation between the ribosomal proteins L5 and L11 in the p53 pathway
Horn, H. F., & Vousden, K. H. (2008) · Oncogene · doi:10.1038/onc.2008.189 · Cited by 140
Multiple facets of junD gene expression are atypical among AP-1 family members
Hernandez, J. M., Floyd, D. H., Weilbaecher, K. N., Green, P. L., & Boris‐Lawrie, K. (2008) · Oncogene · doi:10.1038/onc.2008.120 · Cited by 144
Chromosomal Abnormalities Subdivide Ependymal Tumors into Clinically Relevant Groups
Hirose, Y., Aldape, K., Bollen, A. W., James, C. D., Brat, D. J., Lamborn, K. R., Berger, M. S., & Feuerstein, B. G. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64061-8 · Cited by 139
Regulation of the cell cycle and apoptosis by the oncogenes of adenovirus
White, E. (2001) · Oncogene · doi:10.1038/sj.onc.1204861 · Cited by 141
Cyclin-Dependent Kinase Inhibitors as Anticancer Drugs
Kryštof, V., & Uldrijan, S. (2010) · Current Drug Targets · doi:10.2174/138945010790711950 · Cited by 138
An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2
Evans, S. C., Viswanathan, M., Grier, J. D., Narayana, M., El‐Naggar, A. K., & Lozano, G. (2001) · Oncogene · doi:10.1038/sj.onc.1204533 · Cited by 138
Glycogen synthase kinase3 beta phosphorylates serine 33 of p53 and activates p53's transcriptional activity
Turenne, G. A., & Price, B. D. (2001) · BMC Cell Biology · doi:10.1186/1471-2121-2-12 · Cited by 139
p19 Arf induces p53-dependent apoptosis during Abelson virus-mediated pre-B cell transformation
Radfar, A., Unnikrishnan, I., Lee, H., DePinho, R. A., & Rosenberg, N. E. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13194 · Cited by 140
Self-citation
Spinophilin: from partners to functions
Sarrouilhe, D., Tommaso, A. D., Métayé, T., & Ladevèze, V. (2006) · Biochimie · doi:10.1016/j.biochi.2006.04.010 · Cited by 137
The Mdm2 Oncoprotein Interacts with the Cell Fate Regulator Numb
Juven‐Gershon, T., Shifman, O., Unger, T., Elkeles, A., Haupt, Y., & Oren, M. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.7.3974 · Cited by 135
The tumour suppressor RASSF1A promotes MDM2 self‐ubiquitination by disrupting the MDM2–DAXX–HAUSP complex
Song, M. S., Song, S. J., Kim, S. Y., Oh, H. J., & Lim, D. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.115 · Cited by 137
Induction of SOX4 by DNA damage is critical for p53 stabilization and function
Pan, X., Zhao, J., Zhang, W.-N., Li, H., Mu, R., Zhou, T., Zhang, H., Gong, W.-L., Yu, M., Man, J.-H., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810147106 · Cited by 135
Nucleocytoplasmic Shuttling of p53 Is Essential for MDM2-Mediated Cytoplasmic Degradation but Not Ubiquitination
O’Keefe, K. J., Li, H., & Zhang, Y. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.18.6396-6405.2003 · Cited by 133
Deletions of the INK4A Gene in Superficial Bladder Tumors
Orlow, I., LaRue, H., Osman, I., Lacombe, L., Moore, L., Rabbani, F., Meyer, F., Fradet, Y., & Cordon‐Cardo, C. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65105-x · Cited by 134
Self-citation
p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2.
Esteller, M., Cordon‐Cardo, C., Corn, P. G., Meltzer, S. J., Pohar, K. S., Watkins, D. N., Capellá, G., Peinado, M. A., Matías‐Guiu, X., Prat, J., et al. (2001) · PubMed · Cited by 132
Self-citation
Germline mutation of ARF in a melanoma kindred
Hewitt, C. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.11.1273 · Cited by 132
Covalent and noncovalent modifiers of the p53 protein
Jayaraman, L., & Prives, C. L. (1999) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050271 · Cited by 132
Familial melanoma, pancreatic cancer and germline CDKN2A mutations
Goldstein, A. M. (2004) · Human Mutation · doi:10.1002/humu.9247 · Cited by 130
Mdm2 haplo‐insufficiency profoundly inhibits Myc‐induced lymphomagenesis
Alt, J. R., Greiner, T. C., Cleveland, J. L., & Eischen, C. M. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg133 · Cited by 129
c-Myc Augments Gamma Irradiation-Induced Apoptosis by Suppressing Bcl-X L
Maclean, K. H., Keller, U. B., Galindo, C. R., Nilsson, J. A., & Cleveland, J. L. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.20.7256-7270.2003 · Cited by 128
Cocompartmentalization of p53 and Mdm2 Is a Major Determinant for Mdm2-Mediated Degradation of p53
Xirodimas, D. P., Stephen, C. W., & Lane, D. P. (2001) · Experimental Cell Research · doi:10.1006/excr.2001.5314 · Cited by 127

Authors: Pomerantz, J., Schreiber-Agus, N., Liégeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.-W., Cordon-Cardo, C., & DePinho, R. A.
Affiliations: Albert Einstein College of Medicine (US)
Memorial Sloan Kettering Cancer Center (US)
Corresponding author: DePinho, Ronald A
ORCID: Pomerantz, Jason
Liégeois, Nanette J
Chen, Ken
Orlow, Irene
Lee, Han-Woong
DePinho, Ronald A
Venue: Cell
Publisher: Elsevier BV
Published: 1998-03
Volume: 92
Issue: 6
Pages: 713-723
ISSN: 0092-8674 (ISSN-L)
DOI: 10.1016/s0092-8674(00)81400-2
OpenAlex: W2039463309
Cited by: 1,521
References: 72
Citations by year: 2026: 4 · 2025: 10 · 2024: 6 · 2023: 23 · 2022: 19 · 2021: 23 · 2020: 19 · 2019: 16 · 2018: 12 · 2017: 24 · 2016: 27 · 2015: 32 · 2014: 44 · 2013: 44 · 2012: 47
FWCI: 64.86
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 5617 d)
Locations: Cell (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (CA 47179, CA 47538, CADK97650, P01CA047179)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords: p19ARF, INK4A, MDM2, p53, tumor suppression, protein-protein interaction, p53 degradation, p53 transactivation, oncogenic transformation, Rb pathway, viral oncoproteins, dominant-negative mutant
MeSH terms: Animals, Biotin, Cell Line, Deoxyuracil Nucleotides, Lens, Crystalline, Neoplasm Proteins, Nuclear Proteins, Osteoblasts, Proteins, Proto-Oncogene Proteins, Staining and Labeling, Transformation, Genetic, Tumor Suppressor Protein p53, Retinoblastoma Protein, Apoptosis, Genes, p16, Tumor Suppressor Protein p14ARF, Mice, Proto-Oncogene Proteins c-mdm2, DNA Fragmentation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2’s inhibition of p53

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks